Drug Trial Radar · NCT01436162
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,105
Actual
Start
Oct 19, 2011
Primary completion
Dec 10, 2013
Study completion Dec 10, 2013
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
Conditions
- Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate )Drug
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
Antidepressant + PlaceboDrug
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 WeeksTime frame: 8 weeks
Locations
101 sites in 11 countries. Site status is shown where the registry gives one.
ResearchOne, Inc.
Scottsdale, Arizona
K&S Professional Research Services, LLC
Little Rock, Arkansas
ATP Clinical Research, Inc.
Costa Mesa, California
Diligent Clinical Trials
Downey, California
Synergy Clinical Reserach Center of Escondido
Escondido, California
Pacific Research Partners, LLC
Oakland, California
Anderson Clinical Research
Redlands, California
BreakThrough Clinical Trials, LLC
San Bernardino, California
MCB Clinical Research Centers
Colorado Springs, Colorado
Florida Clinical Research Center, LLC
Bradenton, Florida
Scientific Clinical Research, Inc.
North Miami, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Comprehensive NeuroScience, Inc.
St. Petersburg, Florida
Janus Center for Psychiatric Research
West Palm Beach, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
Atlanta Institute of Medicine & Research
Atlanta, Georgia
Pedia Research
Newburgh, Indiana
Heartland Research Associates
Wichita, Kansas
Louisiana Clinical Research, LLC
Shreveport, Louisiana
Comprehensive Psychiatric Associates
Gladstone, Missouri
The Center for Pharmaceutical Research
Kansas City, Missouri
Mercy Health Research
St Louis, Missouri
Bio Behavioral Health
Toms River, New Jersey
Brooklyn Medical Institute
Brooklyn, New York
Medical & Behavioral Health Research, PC
New York, New York
Midwest Clinical Research Center
Dayton, Ohio
North Star Medical Research, LLC
Middleburg Heights, Ohio
Sooner Clinical Research
Oklahoma City, Oklahoma
Lehigh Center for Clinical Research
Allentown, Pennsylvania
Belmont Center for Comprehensive Treatment
Philadelphia, Pennsylvania
Medical University South Carolina Anxiety Disorder Program
North Charleston, South Carolina
Psychiatric Consultants, PC
Franklin, Tennessee
Research Strategies of Memphis, LLC
Memphis, Tennessee
KRK Medical Research
Dallas, Texas
Future Search Trials of Dallas, LP
Dallas, Texas
Clinical Trials of Texas, Inc.
San Antonio, Texas
Dr Lieven De Weirdt
Sint-Niklaas, Belgium
Saint Anne s.r.o.
Brno, Czechia
Psychiatricka ambulance
Brno, Czechia
Medicana s.r.o.
Hořovice, Czechia
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.